Related Experiment Video
Updated: May 1, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Utility of ProGRP determinations in cancer patients
Ewa Wojcik1, Urszula Rychlik, Piotr Skotnicki
1Department of Clinical Biochemistry, Center of Oncology, M. Sklodowska-Curie Memorial Institute, Cracow Division, Poland.
Background:
The aim of this study was to assess the utility of ProGRP determinations in patients with selected cancer localization, during and after therapy.
Materials And Methods:
The study involved a reference group and a population of lung, breast, ovarian, and prostate cancer patients. ProGRP was evaluated using two-step chemiluminescent microparticle immunoassay (CMIA) manufactured by Abbott Diagnostics, and Architect i2000 analyzer.
Results:
During follow-up of SCLC patients, an increased value for ProGRP was found in 51% and for NSE only in 25.5% of the patients, whereas in NSCLC patients, percentages with elevated ProGRP and CYFRA 21-1 were 8.6% and 55.7%, respectively. SCLC patients also had the highest AUC values for ProGRP. In other cancers, the frequency of elevated ProGRP results were as follows: 13.1%--in breast cancer patients, 19.6%--in ovarian cancer patients, and 15.1%--in prostate cancer patients.
Conclusions:
The presented study revealed that ProGRP is a tumor marker of choice in SCLC, because of its high diagnostic specificity in relation to the reference group and to the group with other malignancies.
